Tumor protein p53 regulated apoptosis-inducing protein 1 (TP53AIP1)

TP53AIP1 encodes a mitochondrial membrane protein, transcriptionally activated by p53 in response to severe DNA damage. It facilitates apoptosis by promoting cytochrome c release and activating caspase-9 and caspase-3, leading to apoptosis execution. TP53AIP1 levels are often reduced in multiple cancer types, correlating with poor prognosis. Overexpression results in cell cycle arrest (primarily at G0/G1) and strong activation of apoptotic pathways, partly through inhibition of the PI3K/Akt pathway. Research suggests TP53AIP1 is a promising therapeutic target for enhancing tumor cell apoptosis, improving cancer outcomes, and is regarded as a candidate biomarker for cancer prognosis. Key scientific details: Located on the mitochondrial membrane; transactivated by p53 after severe DNA damage, especially when p53 is phosphorylated at Ser46. Functions mainly in p53-dependent apoptosis, rather than receptor or enzyme signaling. Expression is tissue-specific (highest in thymus) and downregulated in multiple cancers. No approved drugs directly target TP53AIP1, but future therapies may exploit its apoptotic functions. Safety concerns are mainly theoretical—unintended cell death if poorly targeted. Summary: TP53AIP1 (Tumor protein p53 regulated apoptosis-inducing protein 1) is a mitochondrial apoptosis effector and tumor suppressor activated by p53, critical in p53-dependent cell death and cancer suppression. It is a valid therapeutic target and biomarker in oncology, with ongoing research on modulating its activity to enhance cancer cell clearance without harming normal tissues.

Other names

TP53AIP1p53-regulated apoptosis-inducing protein 1p53AIP1TPIP1

Therapeutic strategies would aim to: Upregulate TP53AIP1 expression to increase apoptosis and cell cycle arrest. Potential indirect modulation via p53 pathway activation (for example, drugs restoring wild-type p53 function could raise TP53AIP1 levels).